InsiderSignalSign in

← Insider buys

DNTH

Dianthus Therapeutics, Inc. · Healthcare

Insiders sold $53.8M of Dianthus Therapeutics, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$53.8MSold, 12 mo

$4.3BMarket cap

DNTH over the last year

No insider buys filed in this year

DNTH after insider buys

3 months after each buy, from the first price a copier could get.

−19.9%Average

−29.4 ptsVs S&P 500

1 of 5Higher

5 buys since 2023 with 3 months of prices.

Every filing

23 insider filings since 2023, newest first

Edward Carr · Chief Accounting Officer

$2.0M−100.0%Sep 18

Simrat Randhawa · EVP, Head of R&D

$2.5M−85.3%Sep 3

Simon Read · Director

$327K−100.0%Aug 19

Anne Mcgeorge · Director

$845K−100.0%Aug 11

Simon Read · Director

$304K−100.0%Aug 11

Adam M Veness · SVP, General Counsel and Sec.

$2.2M−100.0%Aug 11

Marino Garcia · CEO and President

$17.9M−71.8%Aug 7

Ryan Savitz · EVP, CFO & CBO

$3.2M−100.0%Jul 13

Adam M Veness · SVP, General Counsel and Sec.

$2.4M−100.0%Jun 18

Simrat Randhawa · EVP, Head of R&D

$2.4M−86.9%Jun 2

Paula Soteropoulos · Director

$51K−100.0%May 11

Ryan Savitz · EVP, CFO, CBO

$739K−100.0%Apr 10

Ryan Savitz · EVP, CFO, CBO

$9.5M−100.0%Apr 1

Paula Soteropoulos · Director

$48K−100.0%Apr 1

Paula Soteropoulos · Director

$2.2M−100.0%Mar 26

Edward Carr · Chief Accounting Officer

$3.6M−100.0%Mar 13

Simrat Randhawa · EVP, Head of R, D

$2.8M−100.0%Mar 13

Ryan Savitz · CFO, CBO

$904K−100.0%Dec 5

Fairmount Funds Management LLC · Director and 10% owner

$336K+1.0%Oct 3

Fairmount Funds Management LLC · Director and 10% owner

$395K+2.0%Sep 28

Simrat Randhawa · Chief Medical Officer

Fairmount Funds Management LLC · Director and 10% owner

$396K+2.0%Sep 21

Fairmount Funds Management LLC · Director and 10% owner

$272K+1.0%Sep 13

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.